Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only one cholesterol-lowering/statin identity claim is supported by the provided label text. Most nut-related efficacy/safety interaction claims are absent from the supplied Lipitor prescribing information and therefore cannot be verified as label-compliant.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin used to lower cholesterol.
Supported as lipid-lowering therapy in 1.2 (indicated to reduce total-C, LDL-C, apo B, and TG and increase HDL-C as adjunct to diet).
Grapefruit inhibits CYP3A4 and can increase plasma concentrations of atorvastatin.
7.2 Grapefruit Juice.
Unsupported Statements
Grapefruit ... can raise Lipitor drug levels and side effect risks like muscle pain.
Label supports increased atorvastatin concentrations with grapefruit (7.2) and discusses increased myopathy/rhabdomyolysis risk with CYP3A4 inhibitors (5.1), but the provided excerpts do not explicitly connect grapefruit to 'side effect risks like muscle pain' wording as a direct label statement for grapefruit.
No known direct interactions exist between nuts and Lipitor.
No nut–atorvastatin interaction information is provided in the supplied label excerpts; absence of mention does not support 'no known direct interactions.'
Nuts do not affect CYP3A4 and do not affect Lipitor absorption.
No label support for nut effects on CYP3A4 or absorption is present in the provided label excerpts.
Nut consumption (e.g., 1–2 ounces daily) safely lowers cholesterol without altering statin efficacy.
No label support for nut intake quantities, safety, or endorsement as an adjunct affecting lipid lowering/atorvastatin efficacy is present in the supplied label excerpts.
Pistachios lower LDL cholesterol by 10–15% in trials with high-cholesterol patients.
No label support for pistachio-specific percentage efficacy claims is present in the supplied label excerpts.
Overeating nuts may lead to weight gain indirectly raising cholesterol.
No label support for nuts/overconsumption causing weight gain or affecting cholesterol indirectly is present in the supplied label excerpts.
Those with tree nut allergies must avoid tree nuts.
No label support for tree nut allergy avoidance guidance is present in the supplied Lipitor prescribing information excerpts.
Rarely, high-fiber nuts might cause mild digestive upset, but this does not impact Lipitor.
No label support for this nut-related GI effect claim or its lack of impact on Lipitor is present in the supplied label excerpts.
No evidence links nuts to statin side effects like rhabdomyolysis.
No label statement addressing nuts as a risk factor (for rhabdomyolysis) or a 'no evidence links' conclusion is present in the supplied label excerpts.
Contradictions
Important Omissions
No label-aligned contraindications, boxed warnings, or formal safety/monitoring guidance were assessed or addressed in the provided extracted claims (e.g., hypersensitivity mention in 4.2 and skeletal muscle warning framework in 5.1).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims assert nut-specific safety/interaction absence and efficacy effects that are not supported by the supplied Lipitor label excerpts. While no direct label contradictions are identified from the provided text, unsupported statements could mislead about interactions or safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Majority of nut-related interaction/efficacy/safety claims are absent from the provided Lipitor prescribing information and therefore cannot be considered FDA-label compliant.
Suggested Improvement
Remove or revise nut-related claims unless the exact FDA label supports them. Retain only statements explicitly supported by the supplied label text (e.g., atorvastatin lipid-lowering indication and grapefruit juice/CYP3A4-induced increased plasma concentrations with consequent myopathy/rhabdomyolysis risk framework).